Trial intelligence / Profile preview

Effect of intravitreal bevacizumab on visual evoked potentials in macular edema

2012-000765-20Phase 4Completed

Sponsor: Kuopio University Hospital
Start: Nov 2015
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics
Countries: 1

Overview

Phase 4, open-label trial of bevacizumab in exudative macular degeneration, diabetic macular edema (DME) and central retinal vein occlusion (CRVO) (3 arms), sponsored by Kuopio University Hospital. Primary endpoint: Change in visual evoked potential after anti-VEGF injections. Started Nov 2015; status: completed.

Drugs

bevacizumab

Conditions

exudative macular degenerationdiabetic macular edema (DME)central retinal vein occlusion (CRVO)

Beyond the preview

Go deeper on 2012-000765-20.

Study design, results and competitive context are available in the Gosset platform where reported.

Study design & results

Available in the Gosset platform where reported.

Competitive context

Available in the Gosset platform where reported.

Bring the full picture into focus.

See how Gosset can support your research on 2012-000765-20.